Pluto Biosciences, a Denver, CO-based life sciences software-as-a-service (SaaS) platform, closed a $3.7m seed funding round.
The round was led by Silverton Partners.
The company intends to use the funds to further build out the product and go-to-market teams, and develop advanced product features.
Led by Rani Powers, PhD, CEO and Founder, Pluto provides a platform that gives scientific teams both a unified home for managing their biological data, and an interactive canvas for analyzing and visualizing complex biological data sets using no-code computational biology pipelines. Scientists currently use the system to accelerate biological applications spanning from preclinical and translational science research, to cell and gene therapies, drug discovery and development, and clinical research. Built to be flexible for the wide range of experiments a scientific team can perform, the platform can be used to analyze data from popular next-generation sequencing-based assays such as RNA-seq, ChIP-seq, CUT&RUN, and CRISPR screens, as well as data from other workhorse assays for pharma and biotech including metabolomics, proteomics, biochemical assays, and animal behavioral studies. The platform also integrates with sequencing services, electronic lab notebooks, project management platforms, and other collaboration tools.
Since its launch in 2021 from the Wyss Institute at Harvard University, Pluto has become a partner for life sciences organizations in the US and UK, ranging in size and domain from academia to public biopharma. With its biology-focused user experience, Pluto offers flexibility when running bioinformatics analyses and creating plots, allowing researchers to focus on making discoveries and presenting them for maximum impact.
FinSMEs
02/05/2023